Icotinib Hydrochloride is primarily used as a targeted therapy for the treatment of non-small cell lung cancer (NSCLC). It functions as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which helps in blocking the signaling pathways that promote cancer cell growth and proliferation. This makes it particularly effective in patients with EGFR mutation-positive NSCLC. The drug is often administered orally, providing a convenient treatment option for patients. Its targeted approach minimizes damage to normal cells, reducing the severity of side effects compared to traditional chemotherapy. Icotinib Hydrochloride has shown significant efficacy in improving progression-free survival and overall response rates in clinical studies, making it a valuable option in the management of advanced or metastatic NSCLC.